Polomar Health Services (PMHS) Stock Price, Financials & Analysis

Key Stats

Market Cap3.39 Mn

P/E-0.35

P/S1.07

Total Debt (Qtr)794,787.00

Revenue Growth (1y) (Qtr)27,847.07

Add ratio to table…

About

Polomar Health Services, Inc. operates a licensed retail compounding pharmacy in Palm Harbor, Florida that prepares sterile and non sterile custom medications for patients across twenty eight states. The company also owns SlimRx, an online platform that connects patients with licensed physicians to prescribe weight loss treatments, and it is preparing to launch PoloMeds, a service focused on diabetes, erectile dysfunction and dermatological prescriptions. In addition,…

Revenue is generated primarily from the sale of compounded prescription medications dispensed through its pharmacy. Additional income comes from consultation and service fees collected via the SlimRx platform for weight loss treatment programs. The forthcoming PoloMeds service is expected to generate revenue from diabetes, erectile dysfunction and dermatological prescription sales once launched. The company also earns fees from providing prescription fulfillment services to third party telehealth platforms on a wholesale basis.

Polomar Health Services, Inc. operates in the niche markets of sterile compounding pharmacy and digital health telehealth services. It faces competition from established compounding pharmacies such as Fagron and PCCA, as well as from telehealth companies like Ro and Hims & Hers that offer prescription fulfillment. Its competitive advantages include holding a special sterile compounding permit that allows it to dispense injectable medications, maintaining licenses in twenty eight states with plans to expand to most U. S. states by the end of twenty twenty five, and possessing a worldwide non exclusive license to use patent pending technology for delivering medications containing metformin, eletriptan, semaglutide, liraglutide and sildenafil.

The company serves patients who seek custom compounded medications, individuals looking for weight loss therapies through SlimRx, and future clients needing diabetes, erectile dysfunction or dermatological treatments via PoloMeds. It also provides services to third party telehealth platforms that require a reliable prescription fulfillment partner.

How Polomar Health Services ranks

Ranked against the 673 companies in Pharmaceuticals and Biotechnology58 metrics · as of Oct 16, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.35xMedian 17.3x 12^th
P/FCFNegative free cash flow −488xMedian 17.9x 84^th
P/Operating cash flowNegative operating cash flow −488xMedian 16.4x 83^rd
P/S 1.07xMedian 9.48x 90^th
P/BNegative shareholder equity −3.21xMedian 2.17x Not meaningful —
P/Tangible bookNegative tangible equity −3.21xMedian 2.41x Not meaningful —
EV/EBITDANegative EBITDA −46.6xMedian 16.1x 76^th
EV/EBITNegative EBIT −0.43xMedian 19.7x 12^th
EV/Revenue 1.26xMedian 6.87x 87^th
EV/FCFNegative free cash flow −576xMedian 19.3x 80^th
EV/Operating cash flowNegative operating cash flow −576xMedian 16.2x 80^th
PEG (3Y EPS CAGR) —Median 0.35 No data —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 7,689%Median 10.1% 99^th
Revenue CAGR (3Y) —Median 10.1% No data —
Gross profit growth (1Y) 7,674%Median 10.6% 99^th
Gross profit CAGR (3Y) —Median 10.7% No data —
Operating income growth (1Y) −386%Median −0.5% 4^th
Operating income CAGR (3Y) −200%Median 1.5% 1^st
Net income growth (1Y) −361%Median −6.1% 6^th
Net income CAGR (3Y) −201%Median −1.2% 1^st
EPS growth (1Y) −359%Median 20.8% 6^th
EPS CAGR (3Y) —Median 25.2% No data —
Operating cash flow growth (1Y) 99.2%Median 0.0% 94^th
Operating cash flow CAGR (3Y) 67.0%Median 2.4% 98^th
Free cash flow growth (1Y) 99.2%Median 0.0% 93^rd
Free cash flow CAGR (3Y) 67.0%Median 3.2% 98^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 61.1%Median 73.3% 34^th
EBITDA margin −2.7%Median −223% 74^th
Operating margin −295%Median −238% 48^th
Pretax margin −298%Median −229% 47^th
Net margin −301%Median −233% 46^th
FCF margin −0.2%Median −174% 74^th
Operating cash flow margin −0.2%Median −170% 74^th
Return on equity —Median −54.1% No data —
Return on assets −1,422%Median −42.2% 1^st
Return on invested capital —Median −5.3% No data —
Return on capital employed —Median −46.5% No data —
Asset turnover 4.77xMedian 0.18x 99^th
Cash conversion (OCF / net income)Net income is not positive 0.00xMedian 1.20x Not meaningful —
Stock comp / revenue —Median 27.7% No data —

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 97.6%Median 20.0% 7^th
Debt / equityNegative shareholder equity −0.75xMedian 0.26x Not meaningful —
Net debt / EBITDAEBITDA is not positive −7.16xMedian 1.82x Not meaningful —
Debt / FCFFree cash flow is not positive −114xMedian 3.03x Not meaningful —
Liabilities / assets 230%Median 32.8% 6^th
Equity / assetsNegative shareholder equity −130%Median 67.2% 6^th
Interest coverage −90.3xMedian −10.2x 23^rd
Current ratio —Median 4.47x No data —
Quick ratio —Median 3.69x No data —
Cash ratio —Median 3.33x No data —
Altman Z-score —Median −0.74 No data —

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,109.83 Bn	41.55	13.93	54.91 Bn
2	JNJ	Johnson & Johnson	610.61 Bn	29.03	6.24	49.04 Bn
3	ABBV	AbbVie Inc.	500.66 Bn	79.34	7.78	70.82 Bn
4	MRK	Merck & Co., Inc.	354.64 Bn	111.77	5.33	53.91 Bn
5	NVS	Novartis Ag	291.14 Bn	18.46	5.32	9.59 Bn
6	AZN	Astrazeneca Plc	254.18 Bn	24.33	4.33	32.35 Bn
7	AMGN	Amgen Inc	229.46 Bn	26.24	6.02	57.30 Bn
8	PMHS	Polomar Health Services, Inc.	0.00 Bn	-0.35	1.07	0.00 Bn

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

LLY

ELI LILLY & Co

1,109.83 Bn

41.55

13.93

54.91 Bn

JNJ

Johnson & Johnson

610.61 Bn

29.03

6.24

49.04 Bn

ABBV

AbbVie Inc.

500.66 Bn

79.34

7.78

70.82 Bn

MRK

Merck & Co., Inc.

354.64 Bn

111.77

5.33

53.91 Bn

NVS

Novartis Ag

291.14 Bn

18.46

5.32

9.59 Bn

AZN

Astrazeneca Plc

254.18 Bn

24.33

4.33

32.35 Bn

AMGN

Amgen Inc

229.46 Bn

26.24

6.02

57.30 Bn

PMHS

Polomar Health Services, Inc.

0.00 Bn

-0.35

1.07

0.00 Bn

Polomar Health Services PMHS

About

How Polomar Health Services ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Polomar Health Services PMHS

About

How Polomar Health Services ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password